menu
    • menu

    Company profile for Oscotec

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oscotec is a clinical stage drug discovery and development company. Our mission is to create values by translating cutting edge science into innovative medicine for clinically unmet needs. We focus on discovering small molecules with a novel mechanism of action and validating the drug-target-disease hypothesis through rigorous science into clinical proof-of-concept. We aspire to become a leading “discovery engine” that pro...
    Oscotec is a clinical stage drug discovery and development company. Our mission is to create values by translating cutting edge science into innovative medicine for clinically unmet needs. We focus on discovering small molecules with a novel mechanism of action and validating the drug-target-disease hypothesis through rigorous science into clinical proof-of-concept. We aspire to become a leading “discovery engine” that provides the critical impact in developing transformative therapies that will improve patients’ lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oscoteckorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    9F, Bldg. A, Korea Bio-Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gy...
    Telephone
    Telephone
    +82 31 628 7630
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oscotec.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Yatiri Bio Secures Exclusive Option For Denfivontinib In AML
    Yatiri Bio Secures Exclusive Option For Denfivontinib In AML

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261016/0/en/Yatiri-Bio-Enters-Exclusive-Option-to-In-License-Agreement-with-Oscotec-for-Denfivontinib-in-AML.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share
    USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
    USFDA grants ODD to Cevidoplenib for immune thrombocytopenia

    23 Mar 2024

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/news/usfda-grants-odd-to-cevidoplenib-for-immune-thrombocytopenia-15434

    INDIANPHARMAPOST
    23 Mar 2024
    Share Share
    FDA Grants Orphan Drug Designation to Cevidoplenib for ITP
    FDA Grants Orphan Drug Designation to Cevidoplenib for ITP

    21 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-cevidoplenib-for-itp-302095752.html

    PR NEWSWIRE
    21 Mar 2024
    Share Share
    Oscotec/ADEL Initiates Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01
    Oscotec/ADEL Initiates Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01

    23 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oscotecadel-initiates-first-in-human-dosing-in-ph1-of-anti-mtbr-tau-antibody-adel-y01-in-alzheimers-disease-302069432.html

    PR NEWSWIRE
    23 Feb 2024
    Share Share
    Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01
    Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01

    14 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oscotecadel-announce-fda-clearance-of-ind-application-of-adel-y01-for-the-treatment-of-alzheimers-disease-301927556.html

    PR NEWSWIRE
    14 Sep 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search